Фармакологическая эффективность молекул миРНК на модели вирус-индуцированных обострений бронхиальной астмы у мышей

Bronchial asthma (BA) is a heterogeneous disease which characterized by chronic inflammation of the respiratory tract. Respiratory viruses such as the respiratory syncytial virus (RSV) are the main causes of BA exacerbations. Increase of BA incidence stimulates the search for novel targets, which will be suitable for the drug development. Different studies have shown that IL-33 is involved in the pathogenesis of bronchial asthma, but there is no enough information on its role in the pathogenesis of virus-induced of BA exacerbations. Therefore, the purpose of this study was to evaluate the effect of suppression of the il-33 gene by small interfering RNA (siRNA) molecules on the mouse model of RSV-induced BA exacerbations. The local suppression of il-33 gene in lung tissue was shown to decrease the main features of the disease: the pulmonary function was restored, and the degree of pro-inflammatory cells in lungs was reduced. Simultaneously, suppression of il-33 did not alter RSV-infection of respiratory tract. IL-33 was proved to be a promising target for the development of new drugs for the therapy of bronchial asthma and its virus-induced exacerbations.